Additionally, a comprehensive meta-analysis of various cancers treated with anti-CTLA-4 or anti-PD-(L)1 agents found that while rare, fatal toxicities were more prevalent among older patients than their younger counterparts [92]. Here, CTLA4 is linked to cancer.